These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
142 related articles for article (PubMed ID: 37753100)
1. Rare Case of Pediatric Post-transplant Lymphoproliferative Disorder Presenting With Pleural Masses Complicated by Pleural Effusions. Nessim Kostandy E; Wan D; Imseis E ACG Case Rep J; 2023 Sep; 10(9):e01158. PubMed ID: 37753100 [TBL] [Abstract][Full Text] [Related]
2. Occurrence of post-transplant lymphoproliferative disorders among over thousand adult recipients: any role for hepatitis C infection? Burra P; Buda A; Livi U; Rigotti P; Zanus G; Calabrese F; Caforio A; Menin C; Canova D; Farinati F; Luciana Aversa SM Eur J Gastroenterol Hepatol; 2006 Oct; 18(10):1065-70. PubMed ID: 16957512 [TBL] [Abstract][Full Text] [Related]
3. Co-infection of Cytomegalovirus and Epstein-Barr Virus Diminishes the Frequency of CD56 Lam JKP; Azzi T; Hui KF; Wong AMG; McHugh D; Caduff N; Chan KH; Münz C; Chiang AKS Front Immunol; 2020; 11():1231. PubMed ID: 32625211 [TBL] [Abstract][Full Text] [Related]
4. Epstein-Barr virus DNAemia in Iranian liver transplant recipients and assessment of its variation in posttransplant lymphproliferative disorder patients by quantitative polymerase chain reaction assay. Jamalidoust M; Geramizadeh B; Pouladfar G; Namayandeh M; Asaie S; Aliabadi N; Nikeghbalian S; Ziyaeyan M Exp Clin Transplant; 2015 Apr; 13 Suppl 1():306-11. PubMed ID: 25894179 [TBL] [Abstract][Full Text] [Related]
5. Characteristics of Epstein-Barr virus primary infection in pediatric liver transplant recipients. Smets F; Bodeus M; Goubau P; Reding R; Otte JB; Buts JP; Sokal EM J Hepatol; 2000 Jan; 32(1):100-4. PubMed ID: 10673073 [TBL] [Abstract][Full Text] [Related]
6. Primary effusion lymphoma occurring in the setting of transplanted patients: a systematic review of a rare, life-threatening post-transplantation occurrence. Zanelli M; Sanguedolce F; Zizzo M; Palicelli A; Bassi MC; Santandrea G; Martino G; Soriano A; Caprera C; Corsi M; Ricci S; Ricci L; Ascani S BMC Cancer; 2021 Apr; 21(1):468. PubMed ID: 33906629 [TBL] [Abstract][Full Text] [Related]
7. Role of Cytomegalovirus in the Development of Posttransplant Lymphoproliferative Disorders With or Without Epstein-Barr Virus Infection. Namayandeh M; Jamalidoust M; Pouladfar G; Zare M; Ziyaeyan M Exp Clin Transplant; 2022 Aug; 20(8):757-761. PubMed ID: 35037609 [TBL] [Abstract][Full Text] [Related]
8. Early signs and risk factors for the increased incidence of Epstein-Barr virus-related posttransplant lymphoproliferative diseases in pediatric liver transplant recipients treated with tacrolimus. Sokal EM; Antunes H; Beguin C; Bodeus M; Wallemacq P; de Ville de Goyet J; Reding R; Janssen M; Buts JP; Otte JB Transplantation; 1997 Nov; 64(10):1438-42. PubMed ID: 9392308 [TBL] [Abstract][Full Text] [Related]
10. Host microRNAs are decreased in pediatric solid-organ transplant recipients during EBV+ Post-transplant Lymphoproliferative Disorder. Sen A; Enriquez J; Rao M; Glass M; Balachandran Y; Syed S; Twist CJ; Weinberg K; Boyd SD; Bernstein D; Trickey AW; Gratzinger D; Tan B; Lapasaran MG; Robien MA; Brown M; Armstrong B; Desai D; Mazariegos G; Chin C; Fishbein TM; Venick RS; Tekin A; Zimmermann H; Trappe RU; Anagnostopoulos I; Esquivel CO; Martinez OM; Krams SM Front Immunol; 2022; 13():994552. PubMed ID: 36304469 [TBL] [Abstract][Full Text] [Related]
11. In vitro and in vivo evidence that the switch from calcineurin to mTOR inhibitors may be a strategy for immunosuppression in Epstein-Barr virus-associated post-transplant lymphoproliferative disorder. Thieme CJ; Schulz M; Wehler P; Anft M; Amini L; Blàzquez-Navarro A; Stervbo U; Hecht J; Nienen M; Stittrich AB; Choi M; Zgoura P; Viebahn R; Schmueck-Henneresse M; Reinke P; Westhoff TH; Roch T; Babel N Kidney Int; 2022 Dec; 102(6):1392-1408. PubMed ID: 36103953 [TBL] [Abstract][Full Text] [Related]
14. Post-transplant plasma cell myeloma and polymorphic lymphoproliferative disorder with monoclonal serum protein occurring in solid organ transplant recipients. Sun X; Peterson LC; Gong Y; Traynor AE; Nelson BP Mod Pathol; 2004 Apr; 17(4):389-94. PubMed ID: 14976525 [TBL] [Abstract][Full Text] [Related]
15. Post-transplantation lymphoproliferative disorder in heart and kidney transplant patients: a single-center experience. Wasson S; Zafar MN; Best J; Reddy HK J Cardiovasc Pharmacol Ther; 2006 Mar; 11(1):77-83. PubMed ID: 16703222 [TBL] [Abstract][Full Text] [Related]
16. [Post-transplantation lymphoproliferative disorder in childhood]. Stréhn A; Szőnyi L; Kriván G; Kovács L; Reusz G; Szabó A; Rényi I; Kovács G; Dezsőfi A Orv Hetil; 2014 Feb; 155(8):313-8. PubMed ID: 24534879 [TBL] [Abstract][Full Text] [Related]
17. Risk factors and clinical outcomes of pediatric liver transplant recipients with post-transplant lymphoproliferative disease in a multi-ethnic Asian cohort. Huang JG; Tan MYQ; Quak SH; Aw MM Transpl Infect Dis; 2018 Feb; 20(1):. PubMed ID: 29071779 [TBL] [Abstract][Full Text] [Related]
18. Post Transplant Lymphoproliferative Disorder. Gupta D; Mendonca S; Chakraborty S; Chatterjee T Indian J Hematol Blood Transfus; 2020 Apr; 36(2):229-237. PubMed ID: 32425371 [TBL] [Abstract][Full Text] [Related]
19. Hepatitis C virus infection can affect lymphoproliferative disorders only as a cofactor for Epstein-Barr virus in liver transplant recipients: PTLD.Int survey. Khedmat H; Taheri S Exp Clin Transplant; 2012 Apr; 10(2):141-7. PubMed ID: 22432758 [TBL] [Abstract][Full Text] [Related]